Andrew Staron MD
Assistant Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-7011andrew.staron@bmc.org
astaron@bu.edu
Sections
Hematology & Medical Oncology
Biography
Andrew Staron, MD is an Assistant Professor of Medicine in Hematology & Medical Oncology at the Chobanian and Avedisian School of Medicine. He was appointed to this position after completing his residency (2015–2018) and fellowship (2019–2022) at Boston Medical Center. In his third year of fellowship, Dr. Staron was selected for the role of chief fellow. Additionally, he completed a year-long clinical and research fellowship in amyloidosis (2018–2019) at the Boston University Amyloidosis Center, under the mentorship of the director, Dr. Sanchorawala.
As a practicing hematologist at Boston Medical Center, Dr. Staron has a deep commitment to serving patients and families who are affected by various hematologic diseases and who come from diverse backgrounds, drawing upon his own upbringing in an immigrant family. His main research interest is in AL amyloidosis—a rare plasma cell disorder that leads to the accumulation of abnormal immunoglobulin light chain proteins in organs. He has been the lead author on several publications in peer-reviewed journals and given presentations related to AL amyloidosis at national and international meetings. Dr. Staron helps to oversee the clinical database at the Boston University Amyloidosis Center and is directly involved in research projects utilizing this resource. He has conducted natural history studies that described important trends in disease outcomes and explored the role of minimal residual disease assessment in AL amyloidosis. Dr. Staron is also a member of the International Society of Amyloidosis and a peer-reviewer for several journals.
Education
Medicine, MD, New York Medical College
Biology, BS, Cornell University
Publications
Berumen A, Staron A, Kalaitzidis G, Siddiqi OK, Gopal DM, Ruberg FL, Sanchorawala V. Evaluating AL-ISS within a BNP-Based Model for AL Amyloidosis in the Daratumumab Era. Blood Adv. 2026 Apr 17. PMID: 41995749.
Published on 4/15/2026Sanchorawala V, Greatsinger A, Staron A, Berk JL, Mendelson LM, Joshi T, J Burke N, Tabatabaeepour N, Smith J, Signorovitch J. Disease burden of ATTR amyloidosis based on the SF-36® health survey. Cardiooncology. 2026 Apr 15; 12(1). PMID: 41987333.
Published on 4/9/2026Cetin O, Staron A, Mendelson L, Joshi T, Sanchorawala V. Rare dual-clone phenomenon: concurrent ? AL amyloidosis and ?-restricted Bcell lymphoproliferative disorders. Haematologica. 2026 Apr 09. PMID: 41952623.
Published on 3/29/2026George T, Staron A, Burks EJ, Szalat RE, Sanchorawala V. Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis. Br J Haematol. 2026 Jun; 208(6):2252-2255. PMID: 41905782.
Published on 12/29/2025Burke NJ, Mendelson LM, Joshi T, Libbey C, Burks EJ, Prokaeva T, Spencer B, Zheng L, Doros G, Sanchorawala V, Staron A. Detection yield of surrogate tissue biopsies across amyloidosis classes: a large-scale analysis of 4,027 patients. Amyloid. 2025 Dec 29; 1-9. PMID: 41460224.
Published on 9/22/2025Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R. Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis-Related Acquired Factor X Deficiency. Am J Hematol. 2025 Dec; 100(12):2416-2420. PMID: 40981270.
Published on 8/20/2025Joshi T, Prokaeva T, Gopal DM, Verma A, Sanchorawala V, Chen H, Burks E, Dasari S, McPhail ED, Staron A. Wild-Type Transthyretin Amyloidosis in the Kidneys. JACC Case Rep. 2025 Sep 24; 30(29):105132. PMID: 40833310.
Published on 3/25/2025Edwards CV, Ferri GM, Villegas-Galaviz J, Ghosh S, Singh Bawa P, Wang F, Klimtchuk E, Ajayi TB, Morgan GJ, Prokaeva T, Staron A, Ruberg FL, Sanchorawala V, Giadone RM, Murphy GJ. Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition. Amyloid. 2025 Jun; 32(2):179-192. PMID: 40134188.
Published on 1/31/2025Staron A, Sanchorawala V. Current landscape of clinical management for systemic light chain amyloidosis. Future Cardiol. 2025 Mar; 21(4):203-205. PMID: 39885778.
Published on 12/10/2024Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.